Reaction
Large Intestinal Obstruction reporting signals
As of the last recalculation, Large Intestinal Obstruction appears in 2,190 FAERS reports alongside 41 co-occurring drug terms. The strongest observed disproportionality signal is DIMENHYDRINATE (PRR 14.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Dimenhydrinate | 16 | 14.4 | 14.4 |
| Irinotecan Hydrochloride | 19 | 14.2 | 14.2 |
| Leucovorin Calcium | 24 | 12.1 | 12.1 |
| Adalimumab | 605 | 10.8 | 10.9 |
| Niraparib | 25 | 10.8 | 10.8 |
| Atropine | 9 | 10.4 | 10.4 |
| Atropine Sulfate | 11 | 9.7 | 9.7 |
| Bevacizumab | 116 | 9.3 | 9.4 |
| Fluorouracil | 72 | 9.1 | 9.1 |
| Fluorouracil Cream, 0.5% | 71 | 9.1 | 9.1 |
| Risankizumab-Rzaa | 75 | 9.0 | 9.0 |
| Trifluridine And Tipiracil | 10 | 8.9 | 8.9 |
| Umeclidinium | 8 | 8.5 | 8.5 |
| Teduglutide | 12 | 8.5 | 8.5 |
| Oxazepam | 19 | 8.5 | 8.5 |
| Erlotinib | 8 | 7.9 | 7.9 |
| Oxaliplatin | 54 | 7.1 | 7.1 |
| Loperamide Hydrochloride And Dimethicone | 22 | 6.6 | 6.6 |
| Rucaparib | 6 | 6.5 | 6.5 |
| Abiraterone | 9 | 6.3 | 6.3 |
| Mesalamine | 36 | 6.2 | 6.2 |
| Erlotinib Hydrochloride | 8 | 6.1 | 6.1 |
| Panitumumab | 10 | 6.1 | 6.1 |
| Capecitabine | 53 | 5.6 | 5.6 |
| Prochlorperazine | 16 | 5.5 | 5.5 |
| Upadacitinib | 46 | 5.5 | 5.5 |
| Linaclotide | 14 | 5.0 | 5.0 |
| Sevelamer Carbonate | 6 | 5.0 | 5.0 |
| Clozapine | 59 | 4.6 | 4.6 |
| Olaparib | 9 | 4.1 | 4.1 |
| Regorafenib | 5 | 4.1 | 4.1 |
| Encorafenib | 4 | 3.8 | 3.8 |
| Oral Semaglutide | 26 | 3.4 | 3.4 |
| Dornase Alfa | 6 | 2.9 | 2.9 |
| Durvalumab | 6 | 2.8 | 2.8 |
| Enzalutamide | 17 | 2.8 | 2.8 |
| Abiraterone Acetate | 11 | 2.5 | 2.5 |
| Relugolix | 5 | 2.0 | 2.0 |
| Tirzepatide | 24 | 1.4 | 1.4 |
| Droxidopa | 3 | 1.3 | 1.3 |
| Pimavanserin Tartrate | 6 | 1.0 | 1.0 |